Corbus Pharmaceuticals Holdings (CRBP) Total Non-Current Liabilities (2016 - 2024)

Corbus Pharmaceuticals Holdings has reported Total Non-Current Liabilities for 7 years, with the latest figure at $13.5 million in Q4 2024.

• On a quarterly basis, Total Non-Current Liabilities fell 61.71% year-over-year to $13.5 million in Q4 2024; TTM through Dec 2024 was $13.5 million, a 61.71% decrease from a year earlier, with the FY2024 full-year figure at $13.5 million, down 61.71% from the prior year.
• Total Non-Current Liabilities was $13.5 million for Q4 2024 at Corbus Pharmaceuticals Holdings, down from $13.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $57.0 million in Q4 2020, with the low at $13.5 million in Q4 2024.
• Average Total Non-Current Liabilities over 5 years is $34.2 million, with a median of $34.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities grew 12.76% in 2023, then plunged 61.94% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $57.0 million in 2020, then slumped by 32.3% to $38.6 million in 2021, then declined by 13.73% to $33.3 million in 2022, then gained by 5.51% to $35.1 million in 2023, then tumbled by 61.71% to $13.5 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $13.5 million (Q4 2024), $13.7 million (Q3 2024), and $26.4 million (Q2 2024), per Business Quant data.